Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial

Pulmonary arterial hypertension (PAH) is a condition which may lead to right ventricular failure and early mortality and is an important complication in patients with connective tissue disease (CTD). Previously, the endothelin A selective receptor antagonist, ambrisentan, demonstrated efficacy and safety in treating patients with PAH due to WHO Group I etiologies. These analyses describe the 3-year efficacy and safety of ambrisentan in patients specifically with CTD associated PAH (CTD-PAH).

Source: Respiratory Medicine CME - June 28, 2016 Category: Respiratory Medicine Authors: Aryeh Fischer, Christopher P. Denton, Marco Matucci-Cerinic, Hunter Gillies, Christiana Blair, James Tislow, Steven D. Nathan Source Type: research